prikaz prve stranice dokumenta Renin-angiotensin-aldosterone system inhibitors lower hemoglobin and hematocrit only in renal transplant recipients with initially higher levels
Pristup korisnicima matične ustanove
Znanstveni rad - Izvorni znanstveni rad
Renin-angiotensin-aldosterone system inhibitors lower hemoglobin and hematocrit only in renal transplant recipients with initially higher levels
European Journal of Internal Medicine, 29 (2016); 98-103. https://doi.org/10.1016/j.ejim.2015.12.014
Mikolašević, Ivana; Zaputović, Luka; Zibar, Lada; Begić, Ivana; Žutelja, Marta; Klanac, Ana; Majurec, Iva; Šimundić, Tihana; Minažek, Marija; Orlić, Lidija

Institucijski repozitorij: Repozitorij Medicinskog fakulteta u Rijeci

Citirajte ovaj rad

Mikolašević, I., Zaputović, L., Zibar, L., Begić, I., Žutelja, M., Klanac, A. ... Orlić, L. (2016). Renin-angiotensin-aldosterone system inhibitors lower hemoglobin and hematocrit only in renal transplant recipients with initially higher levels. European Journal of Internal Medicine, 29., 98-103. doi: 10.1016/j.ejim.2015.12.014

Mikolašević, Ivana, et al. "Renin-angiotensin-aldosterone system inhibitors lower hemoglobin and hematocrit only in renal transplant recipients with initially higher levels." European Journal of Internal Medicine, vol. 29, 2016, str. 98-103. https://doi.org/10.1016/j.ejim.2015.12.014

Mikolašević, Ivana, Luka Zaputović, Lada Zibar, Ivana Begić, Marta Žutelja, Ana Klanac, Iva Majurec, Tihana Šimundić, Marija Minažek i Lidija Orlić. "Renin-angiotensin-aldosterone system inhibitors lower hemoglobin and hematocrit only in renal transplant recipients with initially higher levels." European Journal of Internal Medicine 29 (2016): 98-103. https://doi.org/10.1016/j.ejim.2015.12.014

Mikolašević, I., et al. (2016) 'Renin-angiotensin-aldosterone system inhibitors lower hemoglobin and hematocrit only in renal transplant recipients with initially higher levels', European Journal of Internal Medicine, 29, str. 98-103. doi: 10.1016/j.ejim.2015.12.014

Mikolašević I, Zaputović L, Zibar L, Begić I, Žutelja M, Klanac A, i sur.. Renin-angiotensin-aldosterone system inhibitors lower hemoglobin and hematocrit only in renal transplant recipients with initially higher levels. European Journal of Internal Medicine [Internet]. 2016. [pristupljeno 09.11.2024.];29:98-103. doi: 10.1016/j.ejim.2015.12.014

I. Mikolašević, et al., "Renin-angiotensin-aldosterone system inhibitors lower hemoglobin and hematocrit only in renal transplant recipients with initially higher levels", European Journal of Internal Medicine, vol. 29, str. 98-103, 2016. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:052725. [Citirano: 09.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:052725
Podaci o radu
Naslov (engleski)Renin-angiotensin-aldosterone system inhibitors lower hemoglobin and hematocrit only in renal transplant recipients with initially higher levels
AutorIvana Mikolašević
AutorLuka Zaputović
AutorLada Zibar
MBZ: 254864
AutorIvana Begić
MBZ: 287874
AutorMarta Žutelja
AutorAna Klanac
AutorIva Majurec
AutorTihana Šimundić
AutorMarija Minažek
AutorLidija Orlić
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za internu medicinu)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
We have analyzed effects of renin-angiotensin-aldosterone system (RAAS) inhibitors on evolution of hemoglobin (Hb) and hematocrit (Htc) levels as well as on the evaluation of kidney graft function in stable renal transplant recipients (RTRs) in respect with initially higher or lower Hb and Htc values. The study group comprised of 270 RTRs with stable graft function. Beside other prescribed antihypertensive therapy, 169 of them have been taking RAAS inhibitors We wanted to analyze the effect of the use of RAAS inhibitors on Hb and Htc in patients with initially higher or lower Hb/Htc values. For this analysis, only RTRs that were taking RAAS inhibitors were stratified into two groups: one with higher Hb and Htc (initial Hb ≥150 g/L and Htc ≥ 45%) and another one with lower Hb and Htc (initial Hb<150 g/L and Htc < 45%) values. Thirty-four RTRs with initially higher Hb and 41 RTRs with initially higher Htc had a statistically significant decrease in Hb (p=0.006) and Htc (p<0.0001) levels after 12-months of follow up. In the group of patients with initially lower Hb (135 RTRs) and Htc (128 RTRs) there was a significant increase in Hb (p=0.0001) and Htc (p=0.004) levels through the observed period. The use of RAAS inhibitors has been associated with a trend of slowing renal insufficiency in RTRs (p=0.03). RAAS inhibitors lower Hb and Htc only in RTRs with initially higher levels. In patients with initially lower Hb and Htc levels, the use of these drugs is followed by beneficial impact on erythropoiesis and kidney graft function.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaEuropean Journal of Internal Medicine
Brojčani podacivol. 29, str. 98-103
p-ISSN0953-6205
DOIhttps://doi.org/10.1016/j.ejim.2015.12.014
URN:NBNurn:nbn:hr:184:052725
Datum objave publikacije2016
URL dokumentahttp://bib.irb.hr/790599
Vrsta resursaTekst
Prava pristupaInstitucijski pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2022-03-08 12:34:55